Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

42.90USD
5:46pm BST
Change (% chg)

$-0.43 (-0.99%)
Prev Close
$43.33
Open
$43.40
Day's High
$43.51
Day's Low
$42.87
Volume
852,251
Avg. Vol
3,682,413
52-wk High
$63.69
52-wk Low
$42.87

Latest Key Developments (Source: Significant Developments)

Taisho Pharmaceutical Completes Procedures For Acquisition Of UPSA SAS
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Japan's Taisho Pharmaceutical <4581.T>::COMPLETES PROCEDURES FOR ACQUISITION OF UPSA SAS.  Full Article

Bristol-Myers Squibb Is Planning Divestiture Of Otezla(Apremilast)
Monday, 24 Jun 2019 

June 24 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB PROVIDES UPDATE ON PENDING MERGER WITH CELGENE.BRISTOL-MYERS SQUIBB CO - COMPANY IS PLANNING DIVESTITURE OF OTEZLA® (APREMILAST)..BRISTOL-MYERS SQUIBB CO - DIVESTITURE IS SUBJECT TO FURTHER REVIEW BY FTC AND REQUIRES THAT BRISTOL-MYERS SQUIBB ENTER INTO A CONSENT DECREE WITH FTC.BRISTOL-MYERS - REMAINS ACTIVELY ENGAGED IN DISCUSSIONS WITH U.S. FTC ON FTC'S CONTINUED REVIEW OF PROPOSED CELGENE TRANSACTION.BRISTOL-MYERS SQUIBB CO - CELGENE TRANSACTION CLOSING DATE CURRENTLY EXPECTED TO BE AT END OF 2019 OR BEGINNING OF 2020..BRISTOL-MYERS SQUIBB CO - PROCEEDS OF OTEZLA SALE WILL ALLOW BRISTOL-MYERS SQUIBB TO ACCELERATE ITS POST-CLOSING DELEVERAGING PLANS.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB AND CELGENE HAVE CONCLUDED THEIR PRE-NOTIFICATION PROCESS WITH EUROPEAN COMMISSION.BRISTOL-MYERS SQUIBB CO - FOR CELGENE DEAL, SUBMITTED FORMAL APPLICATION FOR CLEARANCE BY EUROPEAN COMMISSION.  Full Article

Bristol-Myers Presents Updated Data From Mid-Stage Trial Of Empliciti Plus Pomalidomide And Dexamethasone In Multiple Myeloma
Friday, 14 Jun 2019 

June 14 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB PRESENTS UPDATED EFFICACY DATA FROM PHASE 2 TRIAL OF EMPLICITI (ELOTUZUMAB) PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM).BRISTOL-MYERS SQUIBB CO - EMPLICITI-BASED COMBINATION SHOWED IMPROVEMENTS ACROSS EFFICACY ENDPOINTS.BRISTOL-MYERS SQUIBB CO - EMPLICITI-BASED COMBINATION SHOWED IMPROVEMENTS ACROSS EFFICACY ENDPOINTS.BRISTOL-MYERS - IN DESCRIPTIVE ANALYSIS, ADDITION OF EMPLICITI TO POMALIDOMIDE AND DEXAMETHASONE REDUCED RISK OF DEATH BY 46% AMONG PATIENTS WITH RRMM.BRISTOL-MYERS SQUIBB CO - SAFETY RESULTS FOR EPD WERE CONSISTENT WITH PRIMARY ANALYSIS AND WITH PRIOR FINDINGS FOR EMPLICITI AND POMALIDOMIDE REGIMENS.BRISTOL-MYERS SQUIBB - PATIENTS TREATED WITH EPD CONTINUED TO EXPERIENCE SUSTAINED & CLINICALLY RELEVANT OS AND PFS BENEFITS VERSUS PATIENTS TREATED WITH PD.  Full Article

Bristol-Myers Squibb Announces Dividend
Thursday, 13 Jun 2019 

June 13 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES DIVIDEND.BRISTOL-MYERS SQUIBB CO - DECLARED A QUARTERLY DIVIDEND OF FORTY ONE CENTS PER SHARE.  Full Article

Bristol-Myers Squibb Co Announces Extension Of The Expiration Date For Exchange Offers For Celgene Corp Notes
Friday, 24 May 2019 

May 24 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES EXTENSION OF THE EXPIRATION DATE FOR EXCHANGE OFFERS FOR CELGENE CORPORATION NOTES.BRISTOL-MYERS SQUIBB - EXTENDS EXPIRATION DATE FROM 5:00 P.M., NEW YORK CITY TIME, ON JUNE 3, 2019, TO 5:00 P.M., NEW YORK CITY TIME, ON JULY 8, 2019.BRISTOL-MYERS SQUIBB - EXTENSION OF EXPIRATION DATE OF OFFERS TO EXCHANGE NOTES ISSUED BY CELGENE FOR UP TO $19.85 BILLION OF NEW NOTES TO BE ISSUED BY CO.  Full Article

Bristol-Myers Squibb Co Says CEO Giovanni Caforio's 2018 Total Compensation Was $19.4 Mln Vs $18.7 Mln In 2017
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB CO - CEO GIOVANNI CAFORIO'S 2018 TOTAL COMPENSATION WAS $19.4 MILLION VERSUS $18.7 MILLION IN 2017 - SEC FILING.BRISTOL-MYERS SQUIBB CO - CFO CHARLES BANCROFT'S 2018 TOTAL COMPENSATION WAS $7.9 MILLION VERSUS $8.8 MILLION IN 2017 - SEC FILING.BRISTOL-MYERS SQUIBB CO - CEO CAFORIO'S 2018 TOTAL COMPENSATION WAS 173 TIMES MORE THAN THAT OF MEDIAN OF ANNUAL TOTAL COMPENSATION OF ALL EMPLOYEES.  Full Article

Celgene Stockholders Approve Proposed Acquisition By Bristol-Myers Squibb
Friday, 12 Apr 2019 

April 12 (Reuters) - Celgene Corp ::CELGENE STOCKHOLDERS APPROVE PROPOSED ACQUISITION BY BRISTOL-MYERS SQUIBB.CELGENE CORP - CELGENE EXPECTS TRANSACTION TO CLOSE IN Q3 OF 2019.CELGENE CORP - APPROXIMATELY 98% OF VOTES CAST, AND OVER 70% OF SHARES OUTSTANDING AND ENTITLED TO VOTE, VOTED IN FAVOR OF TRANSACTION.  Full Article

Bristol-Myers Says It Is Pleased Celgene Reached Settlement With Alvogen On Revlimid Patent Litigation
Friday, 29 Mar 2019 

March 29 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ISSUES STATEMENT ON CELGENE’S SETTLEMENT WITH ALVOGEN ON REVLIMID® PATENT LITIGATION.BRISTOL-MYERS SQUIBB CO - CONFIDENT IN STRENGTH OF OUR COMBINATION WITH CELGENE.BRISTOL-MYERS SQUIBB CO - CO, CELGENE EXPECT TRANSACTION TO CLOSE IN Q3.BRISTOL-MYERS SQUIBB CO - PLEASED THAT CELGENE HAS REACHED A SETTLEMENT WITH ALVOGEN RELATED TO PATENTS FOR REVLIMID.  Full Article

Starboard To Withdraw Proxy Solicitation to Vote Against Bristol-Myers & Celgene Deal
Friday, 29 Mar 2019 

March 29 (Reuters) - Starboard Value LP::STARBOARD ISSUES STATEMENT ON BRISTOL-MYERS.HAS DECIDED TO WITHDRAW ITS PROXY SOLICITATION TO VOTE AGAINST CELGENE TRANSACTION."CONTINUE TO FEEL STRONGLY THAT PROPOSED TRANSACTION BETWEEN BRISTOL-MYERS AND CELGENE CORPORATION IS A BAD DEAL FOR SHAREHOLDERS".CONTINUE TO INTEND TO VOTE SHARES AGAINST BRISTOL-MYERS AND CELGENE DEAL AT UPCOMING SPECIAL MEETING.  Full Article

Bristol-Myers Squibb And Concerto HealthAI Announce Strategic Agreement
Thursday, 28 Mar 2019 

March 28 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB AND CONCERTO HEALTHAI ANNOUNCE STRATEGIC AGREEMENT.BRISTOL-MYERS SQUIBB - MULTI-YEAR STRATEGIC AGREEMENT WITH CONCERTO HEALTHAI WILL COVER A DIVERSE RANGE OF CANCERS, INTEGRATE MULTIPLE DATA SOURCES.BRISTOL-MYERS SQUIBB CO - WILL USE CONCERTO HEALTHAI'S PLATFORM, EUREKAHEALTH, TO ACCELERATE INSIGHTS.  Full Article

Market-based pricing disappearing on blue-chip US loans

NEW YORK, July 18 (LPC) - Market-based pricing is disappearing in US investment grade lending as Credit Default Swaps (CDS) become a less relevant measurement of risk, and lenders feel less need to buy protection against the loans as top companies continue to perform in a stable economy.